Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
4.709
-0.001 (-0.03%)
Nov 21, 2024, 9:38 AM EST - Market open
Lipocine Revenue
Lipocine had revenue of $7.92M in the twelve months ending September 30, 2024, down -358.33% year-over-year. In the year 2023, Lipocine had annual revenue of $-2.85M, down -670.16%.
Revenue (ttm)
$7.92M
Revenue Growth
-358.33%
P/S Ratio
3.17
Revenue / Employee
$466,054
Employees
17
Market Cap
25.18M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | -2.85M | -3.35M | -670.16% |
Dec 31, 2022 | 500.00K | -15.64M | -96.90% |
Dec 31, 2021 | 16.14M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | 164.99K | -263.04K | -61.45% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Equillium | 45.91M |
Allurion Technologies | 34.75M |
DarioHealth | 23.05M |
BioXcel Therapeutics | 2.28M |
Longeveron | 1.85M |
IGC Pharma | 1.18M |
LPCN News
- 3 days ago - Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - PRNewsWire
- 14 days ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - PRNewsWire
- 21 days ago - Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - PRNewsWire
- 6 weeks ago - Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - PRNewsWire
- 6 weeks ago - Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PRNewsWire
- 7 weeks ago - Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - PRNewsWire
- 7 weeks ago - Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - PRNewsWire
- 2 months ago - Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® - PRNewsWire